Intro
CJC-1295 is a synthetic peptide designed to stimulate the release of growth hormone from the pituitary gland.
It is a modified analogue of growth hormone–releasing hormone (GHRH), the natural signaling peptide that tells the pituitary gland to produce and release growth hormone. CJC-1295 has a chemical modification that extends its activity in the body, distinguishing it from shorter-acting GHRH analogues such as Sermorelin.
Online interest in CJC-1295 has grown substantially in longevity, fitness, and hormone-optimization communities. It is frequently discussed alongside Ipamorelin and is sometimes sold as a combined product. However, CJC-1295 is not approved as a prescription medication in most countries, and clinical evidence in humans remains limited.
Key Points
- CJC-1295 is a synthetic GHRH analogue that stimulates growth hormone release from the pituitary gland.
- It carries a chemical modification — sometimes called a Drug Affinity Complex (DAC) — that extends its half-life by enabling it to bind to albumin in the bloodstream.
- Unlike Ipamorelin, which acts on the ghrelin receptor, CJC-1295 acts on the GHRH receptor — a distinct signaling pathway.
- It is not approved as a prescription drug in most countries.
- Human clinical evidence is limited; most research involves animal models or small pharmacological studies.
- Products sold outside regulated pharmaceutical supply chains may vary significantly in purity and quality.
- CJC-1295 is frequently discussed online in combination with ipamorelin, but the evidence for combined use is not established.
What CJC-1295 Is
CJC-1295 belongs to the class of GHRH analogues — synthetic peptides that mimic the body’s natural growth hormone–releasing hormone.
The parent compound it is based on is GHRH(1-29), a fragment of the full GHRH molecule that retains biological activity at the GHRH receptor. Sermorelin is another GHRH(1-29) analogue, but one that is cleared from the body relatively quickly. CJC-1295 was developed with additional chemical modifications to extend its duration of action.
The most commonly discussed form of CJC-1295 includes a DAC modification that allows the peptide to bind reversibly to albumin — an abundant blood protein — prolonging its circulation time from minutes to days. A related peptide sometimes called Mod GRF(1-29) or “CJC-1295 without DAC” lacks this modification and behaves more like sermorelin; naming conventions in the research and compounding markets are not always consistent.
Tesamorelin is a further example of an approved GHRH analogue, used in a specific regulated context (HIV-associated lipodystrophy), and provides a useful reference point for what a clinically developed GHRH analogue looks like when subjected to full trials.
For a broader overview of peptide drug classes, see Peptide Therapy.
How It Works
CJC-1295 binds to the GHRH receptor on cells in the anterior pituitary gland, triggering the synthesis and pulsatile release of growth hormone.
Growth hormone acts on multiple tissues and influences:
- fat metabolism
- muscle maintenance
- bone density
- energy regulation
- tissue repair processes
The DAC modification in CJC-1295 allows it to bind reversibly to albumin in plasma, which protects the peptide from rapid enzymatic degradation. This results in a substantially longer half-life compared to unmodified GHRH analogues, which may translate to more sustained elevation of growth hormone and its downstream marker, IGF-1 (insulin-like growth factor 1).
This mechanism is distinct from that of Ipamorelin and other growth hormone releasing peptides (GHRPs), which work through the ghrelin receptor (GHS-R1a). The two receptor pathways converge on growth hormone release but differ in their broader hormonal effects. These differences are sometimes cited as a rationale for combining the two peptide classes, though the clinical implications of this in humans are not established.
Claimed Uses and Evidence
Online sources and some clinics discuss CJC-1295 in the context of several goals:
- reducing body fat
- increasing lean muscle mass
- improving recovery from exercise or injury
- improving sleep quality
- general anti-aging or longevity applications
- enhancing growth hormone and IGF-1 levels
What the evidence shows:
A small number of studies have examined CJC-1295 in human subjects. An early Phase II study, often cited in online discussions, demonstrated that CJC-1295 with DAC produced dose-dependent increases in serum growth hormone and IGF-1 levels lasting several days after a single injection. This confirms pharmacological activity, but it is not the same as demonstrating clinical benefit for any of the claimed uses above.
Animal studies have explored effects on growth hormone levels and related physiological markers.
Large, randomized controlled trials demonstrating clinical benefit in healthy adults are not available for body composition, aging, recovery, or related outcomes.
Online interest in CJC-1295 substantially exceeds what the published scientific literature can support. The existence of measurable hormonal effects does not establish that these changes produce meaningful or safe clinical outcomes in the populations using these peptides. Claims about body composition, anti-aging, or recovery should be treated as unproven until higher-quality human research is available.
Risks and Side Effects
Possible side effects noted in available research and clinical reports include:
- injection-site reactions (redness, swelling, pain)
- headaches
- flushing or a sensation of warmth
- water retention or mild swelling
- transient changes in blood sugar
- potential effects on cortisol and prolactin (to a lesser degree than some other GH-axis compounds)
- dizziness or light-headedness
Because CJC-1295 raises growth hormone and IGF-1 levels — potentially for extended periods due to its long half-life — theoretical concerns with prolonged use include:
- effects on glucose metabolism and insulin sensitivity, as elevated growth hormone can be counterregulatory to insulin
- potential effects associated with chronically elevated IGF-1, which has been studied in relation to cellular proliferation
- hormonal axis disruption with sustained use
Long-term safety data in humans is not established. The extended duration of action of the DAC form means that pharmacological effects, once initiated, may persist for days, limiting the ability to rapidly adjust exposure if adverse effects occur.
Unknown drug interactions, risks from unsupervised dosing, and the absence of post-marketing surveillance data add further uncertainty.
Medical supervision is recommended for anyone considering hormone-related therapies.
Regulation and Product Quality
CJC-1295 is not approved as a prescription medication in most countries, including the United States.
In recent years, regulatory agencies including the US Food and Drug Administration (FDA) have moved to restrict the compounding and commercial sale of CJC-1295 and related peptides. The FDA has classified several growth hormone secretagogues — including GHRH analogues — as unsuitable for compounding, citing concerns about manufacturing standards, evidence gaps, and safety.
Products marketed as CJC-1295 are often sold as research chemicals, a category that generally does not require the same manufacturing controls as approved pharmaceutical drugs.
Concerns with research-grade peptide products may include:
- inconsistent purity between batches and suppliers
- unknown or unlabeled contaminants
- inaccurate labeling of doses or peptide identity (particularly given inconsistent naming conventions between “CJC-1295 with DAC” and “CJC-1295 without DAC” / Mod GRF)
- absence of clinical-grade quality control or sterility testing
Patients should be aware that products obtained outside regulated pharmaceutical supply chains may not match the compounds studied in research settings. The compounding market for peptides operates under significant regulatory uncertainty, which can change without notice.
FAQ
Q: What is CJC-1295? A: CJC-1295 is a synthetic peptide that mimics growth hormone–releasing hormone (GHRH), stimulating the pituitary gland to produce and release growth hormone.
Q: How is CJC-1295 different from ipamorelin? A: CJC-1295 acts on the GHRH receptor, which directly triggers growth hormone release through the same pathway as natural GHRH. Ipamorelin acts on a different receptor — the ghrelin receptor — and belongs to a distinct peptide class called growth hormone releasing peptides (GHRPs). The two pathways are sometimes combined in compounding pharmacy products.
Q: How is CJC-1295 different from sermorelin? A: Both are GHRH analogues based on the same active fragment of GHRH. Sermorelin has a short half-life and is cleared from the body relatively quickly. CJC-1295 with DAC is chemically modified to bind albumin, extending its activity to potentially several days.
Q: What is “CJC-1295 without DAC”? A: This term refers to a related peptide, also called Mod GRF(1-29), that lacks the albumin-binding modification and has a shorter duration of action. Naming conventions are inconsistent across research and compounding markets, and buyers should be cautious about what specific compound they are receiving.
Q: Is CJC-1295 approved as a medication? A: No. CJC-1295 is not approved as a prescription drug in most countries and is typically available only as a research compound.
Q: Is there clinical evidence for CJC-1295? A: Small studies have confirmed that CJC-1295 raises growth hormone and IGF-1 levels in humans. However, there are no large randomized controlled trials demonstrating clinical benefit for body composition, anti-aging, or recovery outcomes in healthy adults.
Q: What are the main risks of CJC-1295? A: Possible side effects include injection-site reactions, headaches, flushing, and water retention. Because it raises growth hormone and IGF-1 levels for extended periods, there are theoretical concerns about glucose metabolism and the effects of chronically elevated IGF-1. Long-term safety data in humans is limited.
Q: Why is CJC-1295 often discussed alongside ipamorelin? A: CJC-1295 and ipamorelin act on different receptor pathways, and it has been suggested that combining them may produce additive effects on growth hormone release. This rationale is sometimes cited by compounding pharmacies. However, the clinical evidence for combination use in humans is not established, and the regulatory and quality concerns that apply to each compound individually apply equally to combination products.
Q: Why are compounded CJC-1295 products a concern? A: Products sold as research chemicals are not subject to the manufacturing and quality standards required for approved medications. Naming inconsistencies, variable purity, and absent sterility testing are documented concerns in this product category.